CDC Recommends COVID-19 Vaccines for Babies

A fresh suggestion to immunise all 20 million children between the ages of 6 months and 5 years old was made public on Saturday by CDC Director Rochelle Walensky. When testing effectiveness against moderate or severe COVID-19 infection, the trials were too small to establish statistical significance. In light of evidence from older children and adults, the FDA permitted both firms to extrapolate efficacy by measuring antibody levels.

In neither the vaccination group nor the placebo group were there any occurrences of severe COVID-19 disease. 4,774 youngsters received the Moderna vaccination, whereas 4,526 received the Pfizer vaccine. Based on 3 instances in the vaccination group and 7 cases in the placebo group in a subgroup of children, Pfizer found that their vaccine was 80% effective in avoiding symptomatic COVID-19.

Even this did not have statistical importance. Its confidence statistic was actually so large that you could drive an aircraft carrier through it. In my 20-year research experience, they reported the widest confidence interval I had ever seen. The vaccination may be linked to a 370 percent higher risk of contracting COVID-19 at one end of the range of possibilities suggested by the confidence interval. In the short term, the Moderna study showed a 38 percent effectiveness in avoiding symptomatic illness—an effect that is known to be fleeting.

Ironically, the vaccination group had higher general hospitalizations (unspecified). Six of the seven kids who needed to be hospitalised were in the vaccination group, and one was in the placebo group, which was only half as big.